Taken together, the previous results of our sFasL-AAV2 study combined with results of the present study with ONL1204 strongly support the value of Fas inhibition as an approach to neuroprotection in glaucoma, both in preserving RGC viability and in preventing neuroinflammation. This evidence concerns the gene FAS and glaucoma.